Exelixis, Inc. (EXEL): who owns it and who trades it
As of Nov 16, 2026, EXEL insiders reported 28 open-market sales worth $34.8M and 1 purchase worth $1.2M in the last 12 months, with 20% of the sale value made under pre-set 10b5-1 plans. The largest seller was Patrick J. Haley (Vice president), with $7.6M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Exelixis
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EXEL
756 funds and institutions reported EXEL shares worth $14.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 11.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 29.08M | 11.57% | $1.6B | -6% |
| California State Teachers Retirement System | 14.79M | 5.88% | $272M | – |
| Farallon Capital Management, L.l.c. | 13.47M | 5.36% | $733M | +3% |
| Renaissance Technologies LLC | 13.43M | 5.34% | $731M | -2% |
| Vanguard Portfolio Management LLC | 12.04M | 4.79% | $655M | -0% |
| AQR Capital Management LLC | 11.02M | 4.39% | $599M | -16% |
| Vanguard Capital Management LLC | 10.95M | 4.36% | $596M | -3% |
| State Street Corp | 9.97M | 3.97% | $542M | -3% |
| Fuller & Thaler Asset Management, Inc. | 8.93M | 3.55% | $486M | +5% |
| Lsv Asset Management | 8.15M | 3.24% | $443M | +5% |
| Geode Capital Management, LLC | 7.65M | 3.04% | $416M | -2% |
| D. E. Shaw & Co., Inc. | 5.55M | 2.21% | $302M | +54% |
| Morgan Stanley | 4.52M | 1.80% | $246M | +8% |
| Invesco Ltd. | 4.50M | 1.79% | $245M | +4% |
| Dimensional Fund Advisors LP | 4.43M | 1.76% | $241M | +3% |
| Arrowstreet Capital, Limited Partnership | 4.37M | 1.74% | $238M | -10% |
| Two Sigma Investments, LP | 4.21M | 1.67% | $229M | +91% |
| Assetmark, Inc | 3.43M | 1.37% | $187M | +1% |
| Nuveen, LLC | 3.28M | 1.30% | $178M | -13% |
| UBS Group AG | 3.17M | 1.26% | $172M | +32% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EXEL insiders reported $1.2M of open-market purchases and $34.8M of sales. 20% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Mary C Beckerle | Director | Sale plan | 9,812 | $53.66 | $527K | Form 4 |
| Jun 1, 2026 | Jack L Wyszomierski | Director | Sale plan | 3,925 | $50.55 | $198K | Form 4 |
| Jun 1, 2026 | Sue Gail Eckhardt | Director | Sale plan | 9,812 | $50.14 | $492K | Form 4 |
| May 26, 2026 | Dana Aftab | Vice president | Sale | 43,451 | $50.35 | $2.2M | Form 4 |
| May 20, 2026 | Patrick J. Haley | Vice president | Sale | 32,110 | $49.81 | $1.6M | Form 4 |
| May 18, 2026 | Christopher J. Senner | CFO | Sale | 34,901 | $50.00 | $1.7M | Form 4 |
| May 18, 2026 | Brenda Hefti | Vice president | Sale plan | 6,625 | $50.21 | $333K | Form 4 |
| May 7, 2026 | Mary C Beckerle | Director | Sale | 7,712 | $48.45 | $374K | Form 4 |
| May 7, 2026 | Maria C Freire | Director | Sale | 20,634 | $46.00 | $949K | Form 4 |
| May 7, 2026 | George Poste | Director | Sale | 60,000 | $45.71 | $2.7M | Form 4 |
| Feb 24, 2026 | Dana Aftab | Vice president | Sale | 47,918 | $44.50 | $2.1M | Form 4 |
| Feb 19, 2026 | Dana Aftab | Vice president | Sale | 29,873 | $44.35 | $1.3M | Form 4 |
| Feb 18, 2026 | Jack L Wyszomierski | Director | Sale plan | 99,574 | $44.01 | $4.4M | Form 4 |
| Feb 18, 2026 | Julie Smith | Director | Sale | 44,087 | $44.50 | $2M | Form 4 |
| Feb 18, 2026 | Julie Smith | Director | Sale | 20,030 | $44.30 | $887K | Form 4 |
| Feb 18, 2026 | Brenda Hefti | Vice president | Sale plan | 18,669 | $44.01 | $822K | Form 4 |
| Feb 17, 2026 | Julie Smith | Director | Sale | 42,422 | $43.33 | $1.8M | Form 4 |
| Feb 17, 2026 | Christopher J. Senner | CFO | Sale | 30,617 | $43.67 | $1.3M | Form 4 |
| Feb 17, 2026 | Patrick J. Haley | Vice president | Sale | 3,036 | $43.84 | $133K | Form 4 |
| Feb 17, 2026 | Patrick J. Haley | Vice president | Sale | 64,778 | $43.50 | $2.8M | Form 4 |
| Feb 13, 2026 | Christopher J. Senner | CFO | Sale | 34,278 | $43.00 | $1.5M | Form 4 |
| Feb 13, 2026 | Sue Gail Eckhardt | Director | Sale plan | 3,856 | $43.79 | $169K | Form 4 |
| Feb 13, 2026 | Bob Oliver | Director | Sale | 21,162 | $43.90 | $929K | Form 4 |
| Feb 13, 2026 | Bob Oliver | Director | Sale | 9,088 | $43.61 | $396K | Form 4 |
| Nov 25, 2025 | Caligan Partners LP +1 | Director | Purchase | 27,532 | $43.12 | $1.2M | Form 4 |
| Nov 21, 2025 | Patrick J. Haley | Vice president | Sale | 28,043 | $42.58 | $1.2M | Form 4 |
| Nov 20, 2025 | Patrick J. Haley | Vice president | Sale | 10,000 | $42.11 | $421K | Form 4 |
| Nov 20, 2025 | Patrick J. Haley | Vice president | Sale | 10,648 | $41.77 | $445K | Form 4 |
| Nov 20, 2025 | Patrick J. Haley | Vice president | Sale | 23,539 | $41.93 | $987K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Patrick J. Haley | EVP, Commercial | – | $7.6M | May 20, 2026 |
| Dana Aftab | EVP, Research and Development | – | $5.6M | May 26, 2026 |
| Julie Smith | Director | – | $4.7M | Feb 18, 2026 |
| Jack L Wyszomierski | Director | – | $4.6M | Jun 1, 2026 |
| Christopher J. Senner | EVP and CFO | – | $4.6M | May 18, 2026 |
| George Poste | Director | – | $2.7M | May 7, 2026 |
| Bob Oliver | Director | – | $1.3M | Feb 13, 2026 |
| Caligan Partners LP | Director | $1.2M | – | Nov 25, 2025 |
| Brenda Hefti | SVP and General Counsel | – | $1.2M | May 18, 2026 |
| Maria C Freire | Director | – | $949K | May 7, 2026 |
| Mary C Beckerle | Director | – | $900K | Aug 10, 2026 |
| Sue Gail Eckhardt | Director | – | $661K | Jun 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EXEL short interest
High short interest. 10.5% of EXEL shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 15%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 25.59M EXEL shares were sold short, 10.5% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 2.19M shares, buying them all back would take about 11.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 25.59M | 10.49% | -6% | 2.19M | 11.7 |
| Oct 15, 2026 | 27.31M | 11.02% | -3% | 2.41M | 11.3 |
| Sep 30, 2026 | 28.18M | 11.37% | +7% | 2.23M | 12.7 |
| Sep 15, 2026 | 26.40M | 10.65% | -8% | 2.13M | 12.4 |
| Aug 31, 2026 | 28.66M | 11.57% | +2% | 1.93M | 14.9 |
| Aug 14, 2026 | 28.03M | 11.31% | -2% | 3.22M | 8.7 |
| Jul 31, 2026 | 28.75M | 11.60% | -7% | 2.14M | 13.4 |
| Jul 15, 2026 | 30.91M | 12.30% | +8% | 2.44M | 12.7 |
| Jun 30, 2026 | 28.54M | 11.35% | -7% | 3.33M | 8.6 |
| Jun 15, 2026 | 30.64M | 12.19% | +3% | 2.26M | 13.5 |
| May 29, 2026 | 29.71M | 11.82% | -2% | 2.40M | 12.3 |
| May 15, 2026 | 30.28M | 12.05% | +1% | 3.30M | 9.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Exelixis company events
Exelixis filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Sep 11, 2026AnnouncementToday, Exelixis, Inc. (Exelixis) announced that on September 10, 2026, the U.S. Food and Drug Administration (FDA) notified Exelixis that it had extended the review period for Exelixis’ new drug application (NDA) for zanzalintinib, in combination with atezolizumab, for the treatment of patients… Filing
- Aug 31, 2026AnnouncementExelixis, inc. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- May 29, 2026LeadershipAt the 2026 Annual Meeting of Stockholders (the Annual Meeting) of Exelixis, Inc. (Exelixis), Exelixis’ stockholders, upon recommendation of Exelixis’ Board of Directors, approved the amendment and restatement of the Exelixis, Inc. 2017 Equity Incentive Plan (as so amended and restated, the 2017… Filing
- May 5, 2026AnnouncementExelixis announced that the Board of Directors authorized the repurchase of up to an additional $750 million of its common stock by December 31, 2027. Filing
- Feb 10, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Exelixis financials
Famous investors that hold EXEL
7 of the 50 well-known investors we track reported holding EXEL in their latest 13F filing. The largest position is Jim Simons's, worth $747M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 12.79M | $747M | 1.0% | -5% |
| Israel Englander · Millennium Management | Q3 2026 | 354,857 | $20.7M | 0.0% | -71% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 328,588 | $19.2M | 0.1% | -18% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 214,045 | $12.5M | 0.0% | +9% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 111,760 | $6.5M | 0.0% | +2313% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 64,832 | $3.8M | 0.0% | -9% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 4,699 | $274K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named EXEL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 9, 2026 | Farallon Capital Management, L.L.C. | 13D/A | 4.9% |
| Nov 9, 2026 | Farallon Capital Management, L.L.C. | 13D/A | 4.9% |
| Nov 9, 2026 | Farallon Capital Management, L.L.C. | 13G | 6.0% |
| Nov 9, 2026 | Farallon Capital Management, L.L.C. | 13G | 6.0% |
Questions about Exelixis, Inc. (EXEL) stock
Who owns the most EXEL stock?
The largest reported owner of Exelixis, Inc. (EXEL) is BlackRock, Inc., with 11.6% of the company. In total, 756 funds and institutions reported holding EXEL at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are EXEL insiders buying or selling?
In the last 12 months, EXEL insiders reported 1 open-market purchase worth $1.2M and 28 sales worth $34.8M. The latest trade was on Aug 10, 2026. See every trade.
What is the short interest in EXEL?
As of Oct 30, 2026, 25.59M EXEL shares were sold short, 10.5% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 2.19M shares, buying them all back would take about 11.7 trading days (days to cover). See the history.
Which famous investors hold EXEL?
7 of the 50 well-known investors we track reported EXEL in their latest 13F filing, including Jim Simons, Israel Englander, Ray Dalio. The largest position is worth $747M. See all holders.
Executive pay
Exelixis's chief executive was paid a total of $33.2M for the year ended Jan 2, 2026, up 161% from $12.7M the year before. In the last 12 months, Exelixis's executives and directors bought no stock on the open market and sold $34.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.